🇺🇸 FDA
Patent

US 12103958

Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions

granted A61KA61K39/001129

Quick answer

US patent 12103958 (Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions) held by The Regents of the University of California expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K39/001129